Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Gross Margin (2020 - 2026)

Maxcyte has reported Gross Margin over the past 6 years, most recently at 119.31% for Q4 2025.

  • Quarterly Gross Margin fell 19307.0% to 119.31% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 127.9% through Dec 2025, up 3198.0% year-over-year, with the annual reading at 127.9% for FY2025, 4628.0% up from the prior year.
  • Gross Margin was 119.31% for Q4 2025 at Maxcyte, down from 76.63% in the prior quarter.
  • Over five years, Gross Margin peaked at 177.99% in Q1 2024 and troughed at 411.21% in Q4 2021.
  • The 5-year median for Gross Margin is 85.66% (2025), against an average of 44.23%.
  • Year-over-year, Gross Margin crashed -55910bps in 2021 and then soared 45795bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 411.21% in 2021, then soared by 111bps to 46.74% in 2022, then plummeted by -592bps to 230.04% in 2023, then surged by 132bps to 73.76% in 2024, then plummeted by -262bps to 119.31% in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Gross Margin are 119.31% (Q4 2025), 76.63% (Q3 2025), and 82.14% (Q2 2025).